Table 2 CERTAIN patients who have been exposed to at least 1 TNF-α inhibitor (population used for primary comparative effectiveness analyses)
All | Anti-TNF agents initiators | Non-anti-TNF agents initiators | Standardized absolute mean difference | |
|---|---|---|---|---|
Total, n | 1321 | 558 | 763 | |
Age (median, IQR), years | 57 [47,65] | 56 [47,64] | 57 [48,66] | 0.137 |
Female, n (%) | 1037 (79.9) | 434 (79.1) | 603 (80.5) | 0.036 |
Caucasian, n (%) | 1091 (83.9) | 446 (81.1) | 645 (85.9) | 0.129 |
RA disease duration (median, IQR), years | 7 [3,14] | 6 [3,12] | 8 [4,15] | 0.213 |
CDAI (median, IQR) | 28 [21,38] | 27 [20,38] | 28 [21,38] | 0.072 |
DAS28-CRP (median, IQR) | 4.9 [4.2,5.6] | 4.7 [4,5.4] | 5.0 [4.3,5.7] | 0.259 |
Biologic Monotherapy, n (%) | 436 (33) | 188 (33.7) | 248 (32.5) | 0.025 |
Concurrent DMARDs, n (%) | 885 (67) | 370 (66.3) | 515 (67.5) | 0.025 |
MTX only, n (%) | 586 (44.4) | 258 (46.2) | 328 (43) | 0.065 |
MTX dose (med, IQR) mg | 20 [15,20] | 20 [15,20] | 20 [15,20] | 0.018 |
MTX plus other DMARDs, n (%) | 95 (7.2) | 40 (7.2) | 55 (7.2) | 0.002 |
Leflunomide only, n (%) | 78 (5.9) | 28 (5) | 50 (6.6) | 0.066 |
Sulfasalazine only, n (%) | 18 (1.4) | 4 (0.7) | 14 (1.8) | 0.100 |
Hydroxychloroquine only, n (%) | 53 (4) | 20 (3.6) | 33 (4.3) | 0.038 |
Concomitant prednisone, n (%) | 460 (34.8) | 198 (35.5) | 262 (34.3) | 0.024 |
Prednisone dose (median, IQR) mg/day | 5 [5,10] | 5 [5,10] | 7 [5,10] | 0.155 |
No use, n (%) | 877 (66.4) | 363 (65.1) | 514 (67.4) | 0.049 |
Prednisone <5 mg, n (%) | 53 (4) | 18 (3.2) | 35 (4.6) | 0.070 |
Prednisone 5- <10 mg, n (%) | 202 (15.3) | 100 (17.9) | 102 (13.4) | 0.125 |
Prednisone ≥ 10 mg, n (%) | 189 (14.3) | 77 (13.8) | 112 (14.7) | 0.025 |
Number of prior biologics exposed to (median, IQR) | 1 [1,2] | 1 [1,2] | 1 [1,3] | 0.427 |
Number of prior non-biologic DMARDs exposed to (median, IQR) | 2 [1,3] | 2 [1,2] | 2 [1,3] | 0.272 |
Biologic started at enrollment, n (%) | ||||
Adalimumab | 122 (9.2) | 122 (21.9) | N/A | N/A |
Infliximab | 127 (9.6) | 127 (22.8) | N/A | N/A |
Etanercept | 101 (7.6) | 101 (18.1) | N/A | N/A |
Golimumab | 71 (5.4) | 71 (12.7) | N/A | N/A |
Certolizumab | 137 (10.4) | 137 (24.6) | N/A | N/A |
Rituximab | 125 (9.5) | N/A | 125 (16.4) | N/A |
Abatacept | 334 (25.3) | N/A | 334 (43.8) | N/A |
Tocilizumab | 304 (23) | N/A | 304 (39.8) | N/A |
Co-morbidities, n (%) | ||||
History of Cardiovascular disease* | 104 (7.9) | 42 (7.5) | 62 (8.1) | 0.022 |
History of Hypertension | 333 (31.9) | 144 (33.6) | 189 (30.7) | 0.063 |
History of Diabetes Mellitus | 102 (10) | 45 (10.8) | 57 (9.5) | 0.042 |
Hyperlipidemia (Defined as: Total cholesterol > 240 mg/dL at baseline visit) | 156 (13) | 70 (13.6) | 86 (12.5) | 0.032 |
History of Malignancy (includes non -melanoma skin cancers) | 100 (7.6) | 41 (7.3) | 59 (7.7) | 0.015 |